Targeting immunoliposomes to EGFR-positive glioblastoma

B Kasenda, D König, M Manni, R Ritschard, U Duthaler, E Bartoszek, A Bärenwaldt, S Deuster, G Hutter, D Cordier, L Mariani, J Hench, S Frank, S Krähenbühl, A Zippelius, C Rochlitz, C Mamot, A Wicki, H Läubli, B Kasenda, D König, M Manni, R Ritschard, U Duthaler, E Bartoszek, A Bärenwaldt, S Deuster, G Hutter, D Cordier, L Mariani, J Hench, S Frank, S Krähenbühl, A Zippelius, C Rochlitz, C Mamot, A Wicki, H Läubli

Abstract

Background: We assessed the capacity of epidermal growth factor receptor (EGFR)-targeted immunoliposomes to deliver cargo to brain tumor tissue in patients with relapsed glioblastoma harboring an EGFR amplification. We aimed to assess the tolerability and effectiveness of anti-EGFR immunoliposomes loaded with doxorubicin (anti-EGFR ILs-dox) in glioblastoma multiforme patients.

Patients and methods: Patients with EGFR-amplified, relapsed glioblastoma were included in this phase I pharmacokinetic trial. Patients received up to four cycles of anti-EGFR ILs-dox. Twenty-four hours later, plasma and cerebrospinal fluid (CSF) samples were obtained. In addition, we also treated three patients with anti-EGFR ILs-dox before resection of their relapsed glioblastoma. Doxorubicin concentrations were measured in plasma, CSF, and tumor tissue. Safety and efficacy parameters were also obtained.

Results: There were no or negligible levels of doxorubicin found in the CSF demonstrating that anti-EGFR ILs-dox are not able to cross the blood-brain barrier (BBB). However, significant levels were detected in glioblastoma tissue 24 h after the application, indicating that the disruption of BBB integrity present in high-grade gliomas might enable liposome delivery into tumor tissue. No new safety issues were observed. The median progression-free survival was 1.5 months and the median overall survival was 8 months. One patient undergoing surgery had a very long remission suggesting that neoadjuvant administration may have a positive effect on outcome.

Conclusions: We clearly demonstrate that anti-EGFR-immunoliposomes can be targeted to EGFR-amplified glioblastoma and cargo-in this case doxorubicin-can be delivered, although these immunoliposomes do not cross the intact BBB. (The GBM-LIPO trial was registered as NCT03603379).

Keywords: blood–brain barrier; cerebrospinal fluid; nanomedicine; pharmacokinetic; targeted therapy.

Conflict of interest statement

Disclosure HL received travel grants and consultant fees from Bristol-Myers Squibb (BMS) and Merck, Sharp and Dohme (MSD); and research support from BMS, Novartis, GlycoEra, and Palleon Pharmaceuticals. BK has received research support from Roche and Abbvie; and consultant fees from Astellas and Riemser. The remaining authors have declared no conflicts of interest.

Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
Recurrent tumor biopsies. Top row: Hematoxylin–eosin (H&E)-stained formalin-fixed tissue; note that B1811381 has cryoartifacts. B1726325 has low levels of residual tumor cells in this biopsy. Bottom row: Anti-epidermal growth factor receptor (EGFR) staining. Black bars represent 20 μm.
Figure 2
Figure 2
Visualization of immune cell types in glioblastoma tissue sections of patients after treatment with anti-epidermal growth factor receptor immunoliposomes loaded with doxorubicin (anti-EGFR ILs-dox). (A) Representative mass cytometric images for patient 2 (left), patient 3 (center), and patient 5 (right) are shown. (B) Quantification of different cell populations including macrophages (CD68 cells), cytotoxic lymphocytes (GranzB), and proliferating cells (Ki67). Frequencies were determined as percentage of total cells. Differences were statistically analyzed by one-way analysis of variance testing. ∗P

References

    1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
    1. Wirsching H.G., Galanis E., Weller M. Glioblastoma. Handb Clin Neurol. 2016;134:381–397.
    1. Wen P.Y., Weller M., Lee E.Q., et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22:1073–1113.
    1. Roth P., Hottinger A.F., Hundsberger T., et al. A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. Swiss Med Wkly. 2020;150:w20256.
    1. Hottinger A.F., Pacheco P., Stupp R. Tumor treating fields: a novel treatment modality and its use in brain tumors. Neuro Oncol. 2016;18(10):1338–1349.
    1. Stupp R., Taillibert S., Kanner A., et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. J Am Med Assoc. 2017;318(23):2306–2316.
    1. Weller M., Le Rhun E., Preusser M., et al. How we treat glioblastoma. ESMO Open. 2019;4(suppl 2):e000520.
    1. Giotta Lucifero A., Luzzi S., Brambilla I., et al. Potential roads for reaching the summit: an overview on target therapies for high-grade gliomas. Acta Biomed. 2020;91(7-S):61–78.
    1. Taal W., Oosterkamp H.M., Walenkamp A.M., et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943–953.
    1. Wick W., Gorlia T., Bendszus M., et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377(20):1954–1963.
    1. Van Den Bent M., Eoli M., Sepulveda J.M., et al. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol. 2020;22(5):684–693.
    1. Yang J., Yan J., Liu B. Targeting EGFRvIII for glioblastoma multiforme. Cancer Lett. 2017;403:224–230.
    1. Eskilsson E., Rosland G.V., Solecki G., et al. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. Neuro Oncol. 2018;20(6):743–752.
    1. Francis J.M., Zhang C.Z., Maire C.L., et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 2014;4(8):956–971.
    1. Choi B.D., Maus M.V., June C.H., et al. Immunotherapy for glioblastoma: adoptive T-cell strategies. Clin Cancer Res. 2019;25(7):2042–2048.
    1. O'Rourke D.M., Nasrallah M.P., Desai A., et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399)
    1. Mamot C., Drummond D.C., Greiser U., et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003;63(12):3154–3161.
    1. Mamot C., Drummond D.C., Hong K., Kirpotin D.B., Park J.W. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat. 2003;6(5):271–279.
    1. Wang D., Sun Y., Liu Y., et al. Clinical translation of immunoliposomes for cancer therapy: recent perspectives. Expert Opin Drug Deliv. 2018;15(9):893–903.
    1. Wicki A., Ritschard R., Loesch U., et al. Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial. Int J Pharm. 2015;484(1-2):8–15.
    1. Mamot C., Ritschard R., Wicki A., et al. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol. 2012;13(12):1234–1241.
    1. Wen P.Y., Macdonald D.R., Reardon D.A., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–1972.
    1. Capper D., Jones D.T.W., Sill M., et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469–474.
    1. Daneman R., Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1):a020412.
    1. Abbott N.J., Ronnback L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7(1):41–53.
    1. Plate K.H., Scholz A., Dumont D.J. Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol. 2012;124(6):763–775.
    1. Chou S.T., Patil R., Galstyan A., et al. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. J Control Release. 2016;244(Pt A):14–23.
    1. Karim R., Palazzo C., Evrard B., Piel G. Nanocarriers for the treatment of glioblastoma multiforme: current state-of-the-art. J Control Release. 2016;227:23–37.
    1. Lee Y.T., Chan K.K., Harris P.A., Cohen J.L. Distribution of adriamycin in cancer patients: tissue uptakes, plasma concentration after IV and hepatic IA administration. Cancer. 1980;45(9):2231–2239.
    1. Chan K.K., Cohen J.L., Gross J.F., et al. Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model. Cancer Treat Rep. 1978;62(8):1161–1171.
    1. Benjamin R.S., Riggs C.E., Jr., Bachur N.R. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res. 1977;37(5):1416–1420.
    1. Zhang Y., Li N., Suh H., Irvine D.J. Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity. Nat Commun. 2018;9(1):6.
    1. Kwong B., Gai S.A., Elkhader J., et al. Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res. 2013;73(5):1547–1558.
    1. Zhou T., Shen Q., Peng H., et al. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab. Ann Hematol. 2018;97(1):141–147.
    1. Meng L., Huang L., Xu Y., et al. Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin. Cancer Chemother Pharmacol. 2020;85(1):3–7.
    1. Inaba K., Arimoto T., Hoya M., et al. Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer. Med Oncol. 2012;29(2):1255–1257.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe